Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + HD-DXM in Newly Diagnosed ITP
NCT05411874Phase 2Unknown
- Sponsor
- Shandong University
- Start
- Oct 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Shandong University. Primary endpoint: Sustained response at 6 months. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05411874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411874.